Humacyte CEO Laura Niklason updates us on the early days of the launch of Symvess, the company's bioengineered blood vessel product

blonca9
7 hours ago
1 min read

She describes the work the company is doing with hospitals and the military to grow uptake as the company launches the product. Plus, pipeline projects in dialysis and PAD.

Coverage brought to you by:

Recent Posts

See All

Biotech veteran Harvey Berger was named Chairman & CEO of Arena BioWorks today - he describes how 'foraging to focusing' will be the name of the game

Stevenage, UK based NRG Therapeutics raised a $67M series B today to advance its aim to restore mitochondrial function and slow the progression of neurodegenerative diseases like Parkinson's and ALS

N-Power Medicine launched what it is calling the 'Industry’s First Prospective External Control Arm Platform' for cancer trials - Mark Lee, CEO and a medical oncologist, explains why and how it works

Humacyte CEO Laura Niklason updates us on the early days of the launch of Symvess, the company's bioengineered blood vessel product

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight